Ruby Wang explains how demographic pressure, public-health crises, long-term planning, technocratic leadership, cultural expectations, state investment, returning scientific talent, and intense competition helped reshape China’s healthcare system. Family stories show how recently basic care and imported medicines were scarce, while today Chinese companies are developing advanced therapies and licensing them abroad. The episode also assesses China’s uneven strengths in biotech, the geopolitical risks of restrictions such as BIOSECURE, the maturity of its digital-health ecosystem, AI doctor avatars, and the continuing burnout and violence faced by clinicians.